Hyperpolarized MRI for GIST on Imatinib

Condition(s) studied

Investigational drug(s) / intervention(s)

Hyperpolarized 13C-MRI: Metabolic MRI using IV injection of hyperpolarized \[1-13C\]pyruvate.

Study summary

Conventional imaging methods, such as CT and MRI, are limited in evaluating GIST response to imatinib, as they mainly reflect tumor size and fail to capture early metabolic or molecular changes. This study investigates GISTs from a metabolic perspective by integrating hyperpolarized (HP) 13C-MRI, metabolomics, and radiomics. HP 13C-MRI enables real-time monitoring of metabolic flux in vivo, while NMR-based metabolomics provides systemic insights. In this single-center, prospective observational cohort study, 30 GIST patients receiving imatinib will undergo pre-treatment CT, HP 13C-MRI, metabolomics, and biopsy. Early response will be assessed at one month, with routine evaluation at four months. Patients will be categorized as responders or non-responders, and multi-omics data will be analyzed using machine learning. The study hypothesizes that metabolic changes detected by HP 13C-MRI can predict treatment response, offering reproducible, quantifiable metrics to improve evaluation and patient care.

Eligibility

Primary outcome measure(s)

• Metabolic activity in spleen measured as pyruvate-to-lactate conversion rate — Data analysis within 7 days after HP 13C-MRI
  The pyruvate-to-lactate conversion calculated by kinetic modeling-based conversion rate of pyruvate-to-lactate (kPL) and model-free metric (signal-to-noise ratio and area-under-curve).

Trial sites (1)

More Chang Gung Memorial Hospital trials in Taiwan

Other trials for the same condition